Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia 20Breast Neoplasms 9Lymphoma 7Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precancerous Conditions 4Lymphoma, Follicular 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Gliosarcoma 3Glioblastoma 3Esophageal Neoplasms 3Congenital Abnormalities 3Central Nervous System Neoplasms 3Adenocarcinoma Of Esophagus 3Wilms Tumor 2Stomach Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2

Interventions

Dexamethasone 27Melphalan 22Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 14Filgrastim 13Bortezomib 12Calcium Dobesilate 9Lenalidomide 7fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5Cyclosporine 5Thalidomide 4Interferon-alpha 4Etoposide 4Busulfan 4miridesap 3dexamethasone acetate 3Radiotherapy 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Carboplatin 3pomalidomide 2liposomal amphotericin B 2ixazomib 2daratumumab 2birtamimab 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoglobulin Light-chain Amyloidosis × Microarray Analysis × Clear all
NCT00520767 2023-12-22

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
35 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡